Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

KBP Biosciences12 enrolled

Overview

This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh Class B) hepatic impairment to evaluate the effect of hepatic impairment on the pharmacokinetics (PK) of KBP-5074.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Moderate Hepatic Impairment Healthy

Interventions

KBP-5074DRUG

KBP-5074 tablet

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Key Inclusion Criteria: 1. Males or females, of any race, between 18 and 80 years of age, inclusive, at screening. 2. Body mass index between 18.0 and 40.0 kg/m2, inclusive, at screening. 3. Subjects with normal hepatic function must be in good health. 4. Subjects must meet the criteria for moderate hepatic impairment based on Child Pugh B. Key Exclusion Criteria: 1. Significant history or clinical manifestation of any medical history, as determined by the investigator not appropriate to participate in this study. 2. Positive serology test results for hepatitis B surface antigen and/or human immunodeficiency virus 1/2. 3. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days or 5 half-lives prior to dosing, whichever is longer. 4. Use of mineralocorticoids or MRAs (eg, spironolactone or eplenerone) within 90 days prior to study drug administration, unless deemed acceptable by the medical monitor and sponsor. 5. Subject has used prescription drugs within 30 days of study drug administration, with the exception of established therapy for hepatic disease and the treatment of associated disorders that have been stable for at least 30 days before study drug administration, as approved by the investigator and in consultation with the medical monitor.

Locations (3)

Orlando Clinical Research Center (OCRC)

Orlando, Florida, United States

Texas Liver Institute (TLI)

San Antonio, Texas, United States

Clinical Trials of Texas (CTT)

San Antonio, Texas, United States

Outcomes

Primary Outcomes

Pharmacokinetic Parameter: Maximum observed concentration (Cmax)

Maximum observed concentration (Cmax) - Plasma

Time frame: 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, and 264 hours postdose.

Pharmacokinetic Paramete: Area under the concentration-time curve from time 0 to infinity (AUC0-∞)

Area under the concentration-time curve from time 0 to infinity (AUC0-∞) - Plasma

Time frame: 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, and 264 hours postdose.

Pharmacokinetic Parameter: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast)

Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast) - Plasma

Time frame: 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, and 264 hours postdose.

Pharmacokinetic Parameter: Time of the maximum observed concentration (tmax)

Time of the maximum observed concentration (tmax) - Plasma

Time frame: 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, and 264 hours postdose.

Safety of KBP-5074 by assessing the number of adverse events, laboratory abnormalities, ECGs, vital signs and physical examinations

Incidence of severity of AEs, laboratory abnormalities (based on hematology, clinical chemistry, and urinalysis test results), ECGs, vital signs, and physical examinations

Time frame: Up to 12 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.